Research/Studies

Why Night Guards Aren’t Enough: Addressing the Neurological Roots of Sleep Bruxism with Biofeedback
Sleep Disorders Research/Studies

Why Night Guards Aren’t Enough: Addressing the Neurological Roots of Sleep Bruxism with Biofeedback

For millions of people, the sound of teeth grinding is more than an annoyance—it’s a nightly neuromuscular storm. Sleep bruxism, characterized by involuntary clenching and grinding of the jaw during sleep, affects an estimated 8%–15% of adults worldwide.¹ Dentists have long turned to night guards as the standard solution, shielding […]

Inspire Medical Systems, Inc. Publishes Inspire V Data at ISSS/AAO-HNS Meetings
Research/Studies Obstructive Sleep Apnea

Inspire Medical Systems, Inc. Publishes Inspire V Data at ISSS/AAO-HNS Meetings

Inspire Medical Systems, Inc. published Inspire V clinical outcomes data from its Singapore clinical study, as well as the Company’s limited market release in the United States, including single-site experience at two leading centers. These data will be presented at the American Otolaryngology-Head and Neck Surgery (AAO-HNS) and International Surgical […]

BetterNight Acquires Coastal and Epoch Sleep Centers to Expand National Sleep Health Services
Research/Studies Industry News

BetterNight Acquires Coastal and Epoch Sleep Centers to Expand National Sleep Health Services

BetterNight, a national leader in comprehensive sleep health solutions, announced the acquisition of Coastal Sleep Diagnostics and Epoch Sleep Centers, two well-established sleep care providers serving communities across the Northeastern United States. The acquisition marks a significant milestone in BetterNight’s mission to improve sleep health outcomes through innovation, personalized care, […]

NOCTEM Health
SleepWorld Magazine Research/Studies

NOCTEM Health

An estimated one in three adults worldwide experience symptoms of insomnia, yet only a fraction of those suffering have access to specialists trained in cognitive behavioral therapy for insomnia (CBTI)—the gold standard in treatment.1,2  This unmet need has created a major bottleneck in behavioral sleep medicine, where demand far exceeds […]

Specific Gut Bacteria Maybe Linked to Insomnia
Insomnia Research/Studies

Specific Gut Bacteria Linked to Insomnia

Specific types of gut bacteria may increase or decrease the risk for insomnia, while insomnia itself may in turn alter the abundance of certain gut bacteria, a new study showed. However, outside experts challenged the investigators’ assertion that the link is causal.  Investigators identified 14 groups of bacteria associated with increased […]

Mental & Behavioral Health Research/Studies Women's Health

Poor Sleep Quality May Worsen Emotional Burden in T2D

Topline: Patients with type 2 diabetes (T2D) who experienced sleep impairments, including short sleep duration, snoring, and insomnia symptoms, were more likely to face an increased risk for diabetes distress. In particular, daytime coping difficulties due to sleep problems showed a notably prominent association with diabetes distress. Methodology: Researchers in Norway conducted a cross-sectional […]

Research/Studies Narcolepsy

Illuminating Narcolepsy’s Neural Pathways

Sleep and wakefulness are carefully balanced by a network of brain regions. Yet for many years, scientists couldn’t pinpoint exactly which neurons regulated sleep state transitions. New research tools and a deeper understanding of brain signaling have led to new discoveries in dopamine and norepinephrine signaling, offering novel insights into […]

Alkermes Announces Initiation of Phase 3 Brilliance Studies Evaluating Alixorexton for the Treatment of Narcolepsy Type 1 and Type 2
Sleep Pharmaceuticals Narcolepsy Research/Studies

Phase 2 Study of Once-Daily Alixorexton in Patients With Narcolepsy Type 1

Alkermes plc today announced positive topline results from the randomized double-blind treatment period of the Vibrance-1 phase 2 study evaluating alixorexton in patients with narcolepsy type 1 (NT1). Alixorexton, formerly referred to as ALKS 2680, is the company’s novel, investigational, oral orexin 2 receptor (OX2R) agonist in phase 2 development as […]